Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiotensin-1-7 - Constant Therapeutics

Drug Profile

Angiotensin-1-7 - Constant Therapeutics

Alternative Names: TXA 127

Latest Information Update: 31 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tarix Orphan; Tarix Pharmaceuticals
  • Developer Constant Therapeutics; Tarix Pharmaceuticals; Unigene Laboratories; US Biotest Inc
  • Class Antihypertensives; Antiretrovirals; Heart failure therapies; Peptide hormones; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Muscular dystrophies; Duchenne muscular dystrophy; Myelodysplastic syndromes; Pulmonary arterial hypertension; Limb girdle muscular dystrophies; Stem cell engraftment
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Connective tissue disorders; Duchenne muscular dystrophy; Epidermolysis bullosa; Limb girdle muscular dystrophies; Muscular dystrophies; Stroke
  • Discontinued Adult respiratory distress syndrome; HIV infections; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Thrombocytopenia

Most Recent Events

  • 22 Jan 2019 Constant Pharmaceuticals is now called Constant Therapeutics
  • 27 Nov 2018 Preclinical trials in Epidermolysis bullosa in USA (PO)
  • 27 Nov 2018 Constant Pharmaceuticals plans a phase II trial for Epidermolysis bullosa (PO) in USA and Europe in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top